Komori
Rohto Pharmaceutical (4527) · PolicyAdvanced

Strategic Shareholdings Held to Maintain and Develop Business Relationships

First written in FY2017. 5 of 6 entries say "Advanced", first in FY2020. Latest entry: FY2026.

6entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017AdvancedFY2020 – FY20262017: 120172018: 020182019: 020192020: 220202021: 020212022: 020222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Business relationships and sales policy through strategic shareholdingsA theme 796 companies write about · 1 as a headwind · 716 as a tailwind

The whole theme swung hardest in 2019: 18 of 141 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 801 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Our policy is to keep the amount of listed and unlisted cross-shareholdings combined at no more than 10% of consolidated net assets, and we maintained this target as of the end of the consolidated fiscal year for the 90th term.」

    The company has specified a quantitative upper limit of no more than 10% of consolidated net assets for cross-shareholdings and continues its annual review of whether holdings should be retained and its policy of reducing them.
  2. FY2024AdvancedAnnual report

    「During the fiscal year, the number of shares held increased for 11 unlisted issues and 3 issues other than unlisted shares, due to initiatives involving technology cooperation and joint development.」

    The company expanded its cross-shareholdings for technology cooperation, joint development, maintaining purchasing relationships and collaboration on social issues. Holdings now comprise 41 unlisted issues and 26 listed or other issues.
  3. FY2023AdvancedAnnual report

    「During the fiscal year, the number of shares held increased for 9 unlisted issues and 4 issues other than unlisted shares, due to business alliances involving technology cooperation, joint development, and development, manufacturing and sales.」

    The company increased its cross-shareholdings for technology cooperation, joint development and business alliances, reporting increases of 9 unlisted issues and 4 listed or other issues. It also continues its policy of conducting an annual review of whether holdings should be retained and reducing holdings whose significance is limited.
  4. FY2021-Q2AdvancedAnnual report

    「At a Board of Directors meeting held on 25 September 2020, the company resolved to sell part of its investment securities and entered into a share transfer agreement on 2 October.」

    For cross-shareholdings and other investment securities, the company resolved to sell part of its holdings to use assets more effectively and has proceeded with the sale, valued at approximately ¥3.2 billion.
  5. FY2020AdvancedAnnual report

    「Once a year, the Board of Directors conducts a detailed review of all listed shares held as cross-shareholdings, specifically examining their importance to business alliances, business relationships and other business strategies, and comprehensively considers the economic rationale of each cross-shareholding, including the benefits and risks associated with holding it, to verify and assess whether it should be retained.」

    The company has established a policy of conducting an annual individual review of cross-shareholdings held to maintain business and technology relationships, and selling and reducing holdings whose significance is limited.
  6. FY2017First statedAnnual report

    「Investment securities held for purposes other than pure investment: 36 issues; total amount recorded on the balance sheet: ¥10,341 million」

    The company discloses holdings of investment securities intended to maintain and develop business relationships with customers, suppliers, banks and technology partners, comprising 36 issues with a total value of ¥10,341 million.
Moved together

"Establishing a market position through high-value-added products and new brands" moved the same way as this thread, in the same document, in 4 of its 6 moves.

444444★123456
  1. ★This thread
  2. 1Establishing a market position through high-value-added products and new brands4×
  3. 2Technological Innovation and Strengthening the R&D Platform4×
  4. 3Globalization Centered on Asia and Expansion into Emerging Markets4×
  5. 4Capital investment in production facilities and research and development functions4×
  6. 5Strengthening Management Oversight by Outside Directors4×
  7. 6Management Focused on Profitability Metrics4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.